Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.70 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.70 |
| ▸ | NAMPT | P43490 | 12/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | STK10 | O94804 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | YES1 | P07947 | 1/20 | 0.43 |
| ▸ | LYN | P07948 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411189 | 0.86 | ACVR2A (0.79) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL447681 | 0.85 | ACVR2A (0.78) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL411467 | 0.85 | ACVR2A (0.65) | ACVR2ATGFBR2NAMPTLMNAPLK4 | |
| SCHEMBL414317 | 0.85 | ACVR2A (0.62) | ACVR2ATGFBR2NAMPTPLK4AURKA | |
| SCHEMBL413519 | 0.85 | ACVR2A (0.70) | ACVR2ATGFBR2NAMPTLMNA | |
| SCHEMBL414446 | 0.84 | ACVR2A (0.64) | ACVR2ATGFBR2NAMPTLMNAPLK4 | |
| SCHEMBL414392 | 0.84 | ACVR2A (0.76) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL6178512 | 0.83 | ACVR2A (0.65) | ACVR2ATGFBR2NAMPT | |
| SCHEMBL21932072 | 0.83 | ACVR2A (0.80) | ACVR2ATGFBR2NAMPTL3MBTL1 | |
| SCHEMBL415573 | 0.83 | ACVR2A (0.72) | ACVR2ATGFBR2NAMPTHDAC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | claimed |
| US-20140120621-A1 | TGF-BETA RECEPTOR INHIBITORS TO ENHANCE DIRECT REPROGRAMMING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147574-A1 | Isothiazole derivatives | SMAD3, SMAD2, TGFBR1 | ACVR2A 85/4885TGFBR2 4/4885NAMPT 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.